Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Kahn

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
AIDS Research and Human Retroviruses|August 1, 1992
A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjectsJ O Kahn, D P Stites, J Scillian, et al.
AIDS (London, England)|December 1, 1990
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I studyJ O Kahn, L D Kaplan, J G Gambertoglio, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1992
CD4 immunoadhesins in anti-HIV therapy: new developmentsS M Chamow, A M Duliege, A Ammann, et al.
Inorganic Chemistry|June 29, 2001
Synthesis, crystal structure, EXAFS, and magnetic properties of catena [mu-tris(1,2-bis(tetrazol-1-yl)propane-N1,N1')iron(II)] bis(perchlorate). First crystal structure of an iron(II) spin-crossover chain compoundP J van Koningsbruggen, Y Garcia, O Kahn, et al.
The Journal of Infectious Diseases|December 12, 2001
Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposureM E Roland, J N Martin, R M Grant, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 2, 1998
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study TeamK Henry, A Erice, C Tierney, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1991
Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complexT L Hodges, J O Kahn, L D Kaplan, et al.
Annals of Internal Medicine|February 15, 1990
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 studyJ O Kahn, J D Allan, T L Hodges, et al.
The New England Journal of Medicine|July 31, 1998
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitorsF M Hecht, R M Grant, C J Petropoulos, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
AIDS Research and Human Retroviruses|August 1, 1992
A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjectsJ O Kahn, D P Stites, J Scillian, et al.
AIDS (London, England)|December 1, 1990
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I studyJ O Kahn, L D Kaplan, J G Gambertoglio, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1992
CD4 immunoadhesins in anti-HIV therapy: new developmentsS M Chamow, A M Duliege, A Ammann, et al.
Inorganic Chemistry|June 29, 2001
Synthesis, crystal structure, EXAFS, and magnetic properties of catena [mu-tris(1,2-bis(tetrazol-1-yl)propane-N1,N1')iron(II)] bis(perchlorate). First crystal structure of an iron(II) spin-crossover chain compoundP J van Koningsbruggen, Y Garcia, O Kahn, et al.
The Journal of Infectious Diseases|December 12, 2001
Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposureM E Roland, J N Martin, R M Grant, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 2, 1998
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study TeamK Henry, A Erice, C Tierney, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1991
Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complexT L Hodges, J O Kahn, L D Kaplan, et al.
Annals of Internal Medicine|February 15, 1990
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 studyJ O Kahn, J D Allan, T L Hodges, et al.
The New England Journal of Medicine|July 31, 1998
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitorsF M Hecht, R M Grant, C J Petropoulos, et al.
Pageof 9